Zai Lab Balance Sheet Health
Financial Health criteria checks 5/6
Zai Lab has a total shareholder equity of $796.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.0B and $240.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$806.45m |
| Equity | US$796.12m |
| Total liabilities | US$240.18m |
| Total assets | US$1.04b |
Recent financial health updates
We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely
Mar 24
Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation
Sep 22We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Jun 02Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans
Jan 20We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Sep 19Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth
Jun 03Recent updates
A Risky Bet: Zai Lab's Uncertain Future
Apr 16Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop
Mar 29We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely
Mar 24Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S
Jan 18Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation
Sep 22Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 24We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Jun 02Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?
Feb 16Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans
Jan 20We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Sep 19Zai Lab GAAP EPS of -$0.14 beats by $0.92, revenue of $48.17M beats by $1.04M
Aug 09China accepts Zai Lab's biologics license application for neuromuscular disorder drug
Jul 13Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth
Jun 03As Losses Narrow, Is Zai Lab Finally Finding Its Winning Formula?
May 18Zai Lab Revenue Triples As It Struggles To Break Cycle Of Mounting Losses
Mar 08Bearish: Analysts Just Cut Their Zai Lab Limited (NASDAQ:ZLAB) Revenue and EPS estimates
Mar 06Financial Position Analysis
Short Term Liabilities: ZLAB's short term assets ($939.6M) exceed its short term liabilities ($203.1M).
Long Term Liabilities: ZLAB's short term assets ($939.6M) exceed its long term liabilities ($37.1M).
Debt to Equity History and Analysis
Debt Level: ZLAB is debt free.
Reducing Debt: ZLAB has no debt compared to 5 years ago when its debt to equity ratio was 1.5%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZLAB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ZLAB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.